Parkinson’s Trial Failure Signals a Likely End for CNS Biotech Aptinyx
Aptinyx’s approach of treating neurological disorders by targeting a key receptor in the brain has fallen short again, this time in Parkinson’s disease. With its third clinical trial failure in less than a year,…
Continue Reading